These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Novel antiplatelet agent ticagrelor in the management of acute coronary syndrome. Ramaraj R; Movahed MR; Hashemzadeh M J Interv Cardiol; 2011 Jun; 24(3):199-207. PubMed ID: 21198849 [TBL] [Abstract][Full Text] [Related]
25. Novel platelet ADP P2Y12 inhibitors in the treatment of acute coronary syndrome. Tan GM; Lam YY; Yan BP Cardiovasc Ther; 2012 Aug; 30(4):e167-73. PubMed ID: 21883998 [TBL] [Abstract][Full Text] [Related]
26. Aspirin, clopidogrel, and ticagrelor in acute coronary syndromes. Berger JS Am J Cardiol; 2013 Sep; 112(5):737-45. PubMed ID: 23751937 [TBL] [Abstract][Full Text] [Related]
27. Cangrelor inhibits the binding of the active metabolites of clopidogrel and prasugrel to P2Y12 receptors in vitro. Judge HM; Buckland RJ; Jakubowski JA; Storey RF Platelets; 2016; 27(3):191-5. PubMed ID: 26270719 [TBL] [Abstract][Full Text] [Related]
28. Current evidence for monitoring platelet reactivity in acute coronary syndrome: a plea for individualized antiplatelet treatment. Aradi D; Sibbing D; Bonello L Int J Cardiol; 2013 Sep; 167(5):1794-7. PubMed ID: 23290951 [TBL] [Abstract][Full Text] [Related]
29. Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction. Alexopoulos D; Xanthopoulou I; Gkizas V; Kassimis G; Theodoropoulos KC; Makris G; Koutsogiannis N; Damelou A; Tsigkas G; Davlouros P; Hahalis G Circ Cardiovasc Interv; 2012 Dec; 5(6):797-804. PubMed ID: 23169985 [TBL] [Abstract][Full Text] [Related]
30. Pharmacotherapeutic considerations for the use of prasugrel and ticagrelor to reduce stent thrombosis in patients with acute coronary syndrome. Piccolo R; Di Gioia G; Niglio T; D'Anna C; De Rosa R; Strisciuglio T; Bevilacqua M; Piscione F; Cirillo P; Galasso G Angiology; 2014 Feb; 65(2):130-6. PubMed ID: 23221279 [TBL] [Abstract][Full Text] [Related]
31. Intrinsic platelet reactivity before P2Y12 blockade contributes to residual platelet reactivity despite high-level P2Y12 blockade by prasugrel or high-dose clopidogrel. Results from PRINCIPLE-TIMI 44. Frelinger AL; Michelson AD; Wiviott SD; Trenk D; Neumann FJ; Miller DL; Jakubowski JA; Costigan TM; McCabe CH; Antman EM; Braunwald E Thromb Haemost; 2011 Aug; 106(2):219-26. PubMed ID: 21713327 [TBL] [Abstract][Full Text] [Related]
32. Clinical significance of residual platelet reactivity in patients treated with platelet P2Y12 inhibitors. Thomas MR; Storey RF Vascul Pharmacol; 2016 Sep; 84():25-7. PubMed ID: 27275527 [TBL] [Abstract][Full Text] [Related]
34. Effects of P2Y12 receptor antagonists beyond platelet inhibition--comparison of ticagrelor with thienopyridines. Nylander S; Schulz R Br J Pharmacol; 2016 Apr; 173(7):1163-78. PubMed ID: 26758983 [TBL] [Abstract][Full Text] [Related]
35. A comparative evaluation of prasugrel and clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Dasbiswas A; Rao MS; Babu PR; Vijayvergiya R; Nayak R; Dani S; Tyagi S; Hiremath S; Patel T; Alexander T; Prakash VS; Singh DP; Yadav MK; Pathak K; Srivastava A J Assoc Physicians India; 2013 Feb; 61(2):114-6, 126. PubMed ID: 24471250 [TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of ticagrelor: a reversible P2Y12 receptor antagonist. Anderson SD; Shah NK; Yim J; Epstein BJ Ann Pharmacother; 2010 Mar; 44(3):524-37. PubMed ID: 20124464 [TBL] [Abstract][Full Text] [Related]
37. p2y12 receptor inhibitors in acute coronary syndromes: from the research laboratory to the clinic and vice versa. Alexopoulos D Cardiology; 2014; 127(4):211-9. PubMed ID: 24458006 [TBL] [Abstract][Full Text] [Related]
38. Elderly patients with acute coronary syndromes managed without revascularization: insights into the safety of long-term dual antiplatelet therapy with reduced-dose prasugrel versus standard-dose clopidogrel. Roe MT; Goodman SG; Ohman EM; Stevens SR; Hochman JS; Gottlieb S; Martinez F; Dalby AJ; Boden WE; White HD; Prabhakaran D; Winters KJ; Aylward PE; Bassand JP; McGuire DK; Ardissino D; Fox KA; Armstrong PW Circulation; 2013 Aug; 128(8):823-33. PubMed ID: 23852610 [TBL] [Abstract][Full Text] [Related]
39. The evolution of antiplatelet therapy in the treatment of acute coronary syndromes: from aspirin to the present day. Angiolillo DJ Drugs; 2012 Nov; 72(16):2087-116. PubMed ID: 23083110 [TBL] [Abstract][Full Text] [Related]
40. The future of platelet function testing to guide therapy in clopidogrel low and enhanced responders. Bernlochner I; Byrne RA; Kastrati A; Sibbing D Expert Rev Cardiovasc Ther; 2011 Aug; 9(8):999-1014. PubMed ID: 21878045 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]